Marti-Massó J F, Poza J J, Lopez de Munain A
Department of Neurology, Hospital Ntra. Sra. de Aránzazu, San Sebastián, Basque Country, Spain.
Therapie. 1996 Sep-Oct;51(5):568-77.
Drug-induced parkinsonism (DIP) is frequent. The list of drugs able to induce parkinsonism is long and probably incomplete, because new drugs, with previously unknown antidopaminergic activity, are constantly being added. Not all the drugs have the same potency for inducing parkinsonism. We classify these drugs in three groups: (1) drugs with obvious antidopaminergic activity which regularly induce parkinsonism; (2) drugs able to induce parkinsonism in particular individuals and (3) drugs which may aggravate Parkinson's disease treated with levodopa. The reports of isolated cases of parkinsonism induced by widely-used drugs (drugs in group 2) may be the result of either an idiosyncratic side effect or a misdiagnosis of parkinsonism. The antidopaminergic activity of the drugs of this group is weak and not sufficiently demonstrated. Maybe, in these cases, the blockage of other neurotransmitters different from dopamine plays a role in the induction of parkinsonism. Probably, the number of patients with DIP is higher than reported or detected, because many patients suffer from weak symptoms that quickly disappear after drug withdrawal. One of the main points of interest is knowing the list, because all these drugs, specially those of group 1, should be avoided or used with caution in the treatment of some common symptomatic problems in patients with Parkinson's disease, such as depression, arterial hypertension, diabetes mellitus and cardiac disorders. The precautions should extent to other populations especially susceptible to suffer from DIP, such as the elderly or patients with other neurodegenerative disorders, such as Alzheimer's disease.
药物性帕金森综合征(DIP)很常见。能够诱发帕金森综合征的药物种类繁多,而且可能并不完整,因为不断有具有此前未知抗多巴胺能活性的新药被研发出来。并非所有药物诱发帕金森综合征的效力都相同。我们将这些药物分为三组:(1)具有明显抗多巴胺能活性且经常诱发帕金森综合征的药物;(2)在特定个体中能够诱发帕金森综合征的药物;(3)可能会使接受左旋多巴治疗的帕金森病病情加重的药物。关于广泛使用的药物(第2组药物)诱发帕金森综合征的个别病例报告,可能是特异质副作用或帕金森综合征误诊的结果。该组药物的抗多巴胺能活性较弱且证据不足。也许在这些病例中,阻断多巴胺以外的其他神经递质在帕金森综合征的诱发中起了作用。很可能,药物性帕金森综合征患者的实际数量高于报告或检测到的数量,因为许多患者症状较轻,在停药后症状很快消失。其中一个主要关注点在于了解这些药物清单,因为在治疗帕金森病患者的一些常见症状问题(如抑郁症、动脉高血压、糖尿病和心脏疾病)时,所有这些药物,尤其是第1组药物,都应避免使用或谨慎使用。这些预防措施应扩展到其他特别容易患药物性帕金森综合征的人群,如老年人或患有其他神经退行性疾病(如阿尔茨海默病)的患者。